Letter to the Editor Regarding "Comparing Cardiovascular Outcomes and Costs of Perindopril-, Enalapril- or Losartan-Based Antihypertensive Regimens in South Africa: Real-World Medical Claims Database Analysis"
Adv Ther. 2024 Nov 19.
doi: 10.1007/s12325-024-03025-2.
Online ahead of print.
1 Health Systems Research Unit, South African Medical Research Council, Cape Town, South Africa. Trudy.Leong@mrc.ac.za.
2 Health Systems Research Unit, South African Medical Research Council, Cape Town, South Africa.
3 Department of Surgery, Nelson R. Mandela School of Medicine, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
4 Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
5 Division of Biostatistics and Epidemiology, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Keywords:
Cardiovascular outcomes; Enalapril; Health systems strengthening; Perindopril; Real-world evidence; Renin–angiotensin–aldosterone system (RAAS) inhibitors; South Africa.